Medical therapies for hepatocellular carcinoma: a critical view of the evidence

@article{Villanueva2013MedicalTF,
  title={Medical therapies for hepatocellular carcinoma: a critical view of the evidence},
  author={Augusto Villanueva and Virginia Hern{\'a}ndez-Gea and Josep M Llovet},
  journal={Nature Reviews Gastroenterology &Hepatology},
  year={2013},
  volume={10},
  pages={34-42}
}
The management of hepatocellular carcinoma (HCC) has substantially changed in the past few decades. Improvements in patient stratification (for example, using the Barcelona Clinic Liver Cancer staging system) and the introduction of novel therapies (such as sorafenib) have improved patient survival. Nevertheless, HCC remains the third most common cause of cancer-related deaths worldwide. Decision-making largely relies on evidence-based criteria, as depicted in the US and European clinical… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 123 CITATIONS, ESTIMATED 59% COVERAGE

212 Citations

0102030'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 212 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 92 REFERENCES

Phase III trial evaluating the addition of tarceva® (erlotinib) to nexavar® (sorafenib) did not provide additional benefit to patients with liver cancer versus nexavar alone

  • Bayer Investor Relations
  • Bayer [online], http://www
  • 2012

Similar Papers

Loading similar papers…